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Abstract
Bisphosphonates are used for treatment of different bone conditions, most frequent‐
ly for increasing bone density in osteoporosis patients and for treatment of primary
or metastatic bone tumor as well as intake for osteoporosis patients.
The pharmacokinetics of bisphosphonates is well described in order to clarify mech‐
anisms of action of each sub-group according to the classification of these drugs.
Bisphosphonate-induced avascular osteonecrosis is described as phenomenon in
the human bones especially observed in human jaws. From pathophysiological
point of view this process is studied describing the osteoclast activity inhibition.
Several studies and results are stated.
Having in mind that this process occurs in cases that do not include bisphospho‐
nates intake, the American Association of Oral and Maxillofacial surgeons accept a
new diagnostic and treatment strategies as well as new name of the disease - Medi‐
cine related osteonecrosis of the jaw.
By comprehensive analysis of all studies by now and cases from our practice, sever‐
al important and significant protocols are introduced in this chapter, effecting diag‐
nosis, treatment preparation, treatment and post-surgical behavior.
Keywords: Bisphosphonate-induced osteonecrosis of the jaw, dental implantology, medi‐
cine related osteonecrosis of the jaw
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
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1. Introduction
Since it was first identified in 2003, bisphosphonate-induced osteonecrosis has been under
growing control by medical and dental specialist alike because it affects cancer patients re‐
ceiving intra-venous bisphosphonate therapy and osteoporosis patients receiving oral bi‐
sphosphonate therapy.
It is of significant importance to introduce the mechanism of action of this type of medica‐
tions, way of distribution and risk of complication during or after treatment with them. A
strategy of preparation, medication support and techniques before, during and after dental
surgery procedures and especially placement of dental implants must be clarified in order to
avoid bisphosphonate-induced osteonecrosis.
2. Indications for bisphosphonates
Even though they were founded in the 18th century, their real clinical usage began only a
hundred years ago with the synthesis of the first bisphosphonate (BP)–etidronate. The
birthplace of these medicines is considered to be the scientific institute in Davos, Switzerland,
where a team headed by Herbert Fleisch, Sylvia Bisaz, and Roman Muhlbauer proved the role
of bisphosphonates in bone metabolism and their importance in bone disorders treatment in
1967.
Figure 1. Normal osteoclast activity and osteoclasts death by bisphosphonate treatment (after R.E. Marx).
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Data concerning pharmacokinetics of diphosphonates, later called bisphosphonates, were
published for the first time in 1969. Forty-five years of experience, including researches, has
significantly manifested the advantages and disadvantages of this drug group.
Inventing and developing bisphosphonates for treatment of different bone conditions is
immense progress in solving fine mechanisms of bone formation and a significant develop‐
ment in medicine as a whole.
Bisphosphonates treatment indications are mainly for increasing bone density in osteoporosis
patients (e.g. alendronate and rizedronate), and intravenous (IV) with mouth intake dosage
for patients with primary or metastatic bone tumor (e.g. pamidronate and zoledronate).
Intravenous intake is also recently tolerated in osteoporosis patients.
Figure 2. Scheme of bone metabolic unit (BMU) (after R.E. Marx).
3. Pharmacokinetics of the bisphosphonates
Bisphosphonates are chemically stable analogs of non-organic pyrophosphates (PPi) related
to skeleton mineralization. Their development is related to inventing inhibitors of calcification
in order to resist hydrolysis with alkaline phosphatase. PPi and BPs could not only slow down
bone growth but also destroy hydroxyapatite crystals. BPs are remarkably efficient inhibitors
to bone resorption during experiments in vitro and in vivo. During the process of their clinical
application in the 1990s, it became clear that in order to clarify the chemical and physical
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reactions, and explain the variety of their biological effects, it is necessary to study the cell to
cell interactions. Bisphosphonates suppress bone resorption by selective absorption to
mineralized bone surface where they counteract to osteoclasts.
Figure 3. Basic molecular structure
Bisphosphonates couldcan be classified to at leastinto two groups with different molecular
action mechanisms. The first one: is nitrogen free bisphosphonates (like etidronate and
clodoronate) that interfere ATP-dependent intercellular ways. The second group is bisphosph‐
onates with nitrogen, they that are more powerful (including pamidronate, alendronate,
rizedronate, ibandronate, and zoledronate) they). They are metabolized differently, by
inhibiting key enzymes of mevalonat/cholesterol biosynthetic way.
Precisely because of the obviously differentobvious biochemical and pharmacological
differencedifferences and uneven intercellular interaction is important the division of, BPs in
tohave been divided into separate groups and their specific usage according to a specific
disease.
They are incorporated in skeletal bone without being degraded. Bisphosphonates are attached
to Ca2+ in areas with increased bone resorption and stay integrated in the bone for 10 to 40
years – alendronate. For example, alendronate’s half-life for example is 12 to 28 years. Once
taken, BPs unlock cascade biochemical processes leading to loss of osteoclast ability to resorb
bone or even to their apoptosis.
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4. Bisphosphonate-induced osteonecrosis of the jaws
It is undoubtedly thatUndoubtedly, the intake increases the quality of life of the treated
patients in general, but negative effecteffects should also be taken in tointo consideration.
Stomach disorders, erosions of the esophagus, uveitis, flueflu-like conditions, muscle and joint
pain, and severe necrosis in the maxillofacial area, known as BONJ – (bisphosphonate
osteonecrosis of the jaw) could appear.
Figure 4. The way to bone fracture by solid bone tumors (after R.E. Marx).
Figure 5. Prevention of bone resorption by bisphosphonate osteoclast inhibition (after R.E. Marx).
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Recently inIn recent literature is found date for, a new type of complication associated with
bisphosphonate intake –has been found, which is called avascular necrosis of the jaws. It is
defined as necrosis associated with or without dental procedures, which could persist for more
than 6-8 weeks with irresponsive to conservative treatment, found in patients without history
of previous radiotherapy in the area affected but treated with nitrogen group bisphosphonates
with nitrogen group, i.v. through IV for at least a year or per os for longer period, and associated
with general condition withof bone resorption. Similar cases arewere published for the first
time in 2003 by Marx with patients treated with pamidronate and zoledronate. Later, Carter
and Gross, Ruggierro, Migliorati, and Wang reportalso reported similar cases. In 2005,
Novartis (Aredia and Zometa48 producer) officially declaredeclared 475 cases of Bisphosph‐
onate bisphosphonate-related osteonecrosis of the jaws. In nowadaysNowadays, the number
of affected patients worldwide is unknown. Scientific literatures says the BONJ is from 1,.3%
to 10%. More There are more than 5,.1 million patients are treated with bisphosphonates. More
and more than 2 million acceptaccepted BPs as antimalignatanti-malignant therapy. The
number of patients treated for osteoporosis with BPs is increasing rapidly. More than 10 million
patients, mainly women in the USA has, have osteoporosis,. It and it is supposed that the
number will increase to 12 million and 34. Thirty-four million patients older than 50 have
decreased bone density and considered high risk for osteoporosis development. Oral BPs
arewere prescribed to more than 70% of the patients diagnosed with osteoporosis in US during
the USA in 2003- to 2006.((American association of Oral and Maxillofacial Surgeons)). More
than 190 million prescriptions arewere issued in North America. In 2003 Alendronate,
alendronate is 19th most prescribed medicine (17 million prescriptions) Risedronate), risedro‐
nate is 72nd (6 million prescriptions) zolendronate), while zoledronate is used from more than
300,000 sick people.
5. Pathophisiology of BONJ
Bisphosphonate-associated osteonecrosis of the jaws is a result of treatment with BPs, bone
metabolism disorders and physiological micro damagemicrodamage of the jaws interferin‐
ginterfere their biomechanical properties. Oral cavity conditions, microtrauma, infections
increase the efforts of the organism to bone recovery, exceeding the ability of the hipodynamic
bone. Compared to all other bones maxilla and mandible are remodeled most frequently in
the human body. This is the reason why BONJ is observed only in jaw-bones. Unlike to other
bones in the human body, they are not enough protected enough. It is an important fact that
only a thin mucosa and a periosteum are the only barriers protecting bone from injuries. From
the other side teeth are prerequisite to easy microorganisms penetration and development of
internal infections–caries and periodontal disease complications. It is interesting to mention
that local factors like partial and full removable dentures are also factors that increase the risk
of osteonecrosis. Smoking and continuous corticosteroid therapy are also risk factors.
According to Denn et al., all osteonecrosis cases describe todescribed in 2006 arewere associ‐
ated with nitrogen containing bisphosphonates. In scientific literature, there is no single
opinion which bisphosphonates exactly leads to more frequent BONJ development. The
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thought that Zoledroniczoledronic acid isis the most dangerous prevails. Most cases of BONJ
are related with i.vIV intake.
In spite of the fact that for BONJ is has been here for a long period of time, factors that initiate
the necrosis are still discussing.being discussed. It would be right to point out that for initiation
of BONJ many factors are responsible with variable priority in different cases.
OnIn the first place, this is the inhibition of osteoclast activity and bone remodeling. But only
this factor is not enough, because similar osteonecrosis would be observed in the other bones.
Bacterial invasion with consequent inflammation is a factor that distinguish the condition in
oral cavity compared to other body parts. The existence of various biofilm in oral cavity is
dictated by different periodonatlperiodontal diseases, caries and its complications and
periapical inflammation. This is a prerequisite for microorganism invasion to the left open
bone left (after extraction, for example). In necroticNecrotic bone fragments after tooth
extraction in BPs treated patients arehave isolated mainly Actinomyces species but also viruses
and fungus. Angiogenesis suppression could also be initiator of jaw osteonecrosis. Medicines
that disturb growth, migration, and differentiation of endothelial cells for new vessel formation
playsplay an important role in avascular osteonecrosis. In addition to these basic factors to
pathogenesis of medication-related osteonecrosis of the jaw (MRONJ could be added),
microtrauma of the jaw during masticatory action and supposed harmful or acquired immune
deficiency could also be added.
6. Prophylaxis and treatment of BONJ
In literature, there is no solidarity concerning bisphosphonate therapy suspension after the
appearance of jaw-osteonecrosis. Marx suggests bisphosphonate therapy in onco-patients to
be discussed with an oncologist in order to define positive effect/risk ratio, having in mind
bisphosphonatebisphosphonate’s half-life (10 years).
In literature thereThere is prevalence of BONJ with prior dental procedures compared to the
so called spontaneous osteonecrosis and 33%–86% of the BONJ in literature are described after
different dental procedures.
Prevailing opinion is that with ageas one gets older the danger from bisphosphonate osteo‐
necrosis increases withby 9%.
Behavior inof diagnosed osteonecrosis patients is dependent on the disease stage. It should be
mentioned that American Association of Oral and Maxillofacial Surgeons proposeproposed a
change in the disease nomenclature formfrom BONJ to Medicine medication-related osteo‐
necrosis of the jaws (MRONJ). The reason is an increasing number of patients with osteonec‐
rosis of the jaws have been diagnosed after other drug intake (denosumab). Due to this reason
Hence, the AAOMS changeschanged the name, which was accepted in 2009, on. On their
consensus conference in 2014, with a Position Paper and in addition to the new name accepts,
they accepted new diagnostic and treatment strategies corresponding to the contemporary
researches., as follows:
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1. I.v.IV bisphosphonates for treatment of primary bone tumors and bone metastasis,
multiple myeloma, and severe osteoporosis but with lower dosage.
2. Oral bisphosphonates mainly for osteoporosis and osteopenia treatment, as well as
PagetPaget’s disease and osteogenesis imperfectimperfecta.
3. DenozumabDenosumab–RANK ligand inhibitor–it inhibits bone resorption by inhibition
of the function of osteoclasts and as an advantage could be mentioned that it is not
connected to the bone so within 6 months after treatment the risk of complications is
slightly noticeable.
4. Antiangiogenetic medications–it is used in different tumor conditions and is useful due
to the fact that preventsto prevent formation of new blood vessels. It connects to signal
molecules responsible for blood vessels formation and interfereinterferes the angiogenesis
signaling cascade.
According to AAOMSAAOMS’s Position Paper, it is possible to think about MRONJ if several
characteristics are present:
1. Antiresorptive or atiangiogenicantiangiogenic treatment conducted before or in the past.,
2. Bone that is exposed in the maxillofacial region through intraoral or extraoral fistula(e)
persisting for more than 8 weeks, and
3. Lack of radiation therapy in the oro-facial region or metastatic disease to the jaws.
It should be mentioned that, according to the AAOMS, risk for osteonecrosis development in
patients with bone tumors treated with zoledronate is 0% to 1%. It is similar in patients treated
with denozumab.denosumab. A bit lower is the valuepercentage risk in patients treated with
antiangiognetic drugs, like bevacizumab –, which is 0.2%. The risk for patients with osteopo‐
rosis treated with denozumabdenosumab and zoledoronate is 0.04%. It should be noted that
with increasingthe longer the period of time for treatment is increasingthe higher the risk for
jaw osteonecrosis form, from 0.5% for one year of treatment to 1.1% for three year years of
treatment. After all it is a matter ofThese are based on retrospective studies of treated patients,
which who have not been treated surgically in the oral cavity but has develophave developed
spontaneous osteonecrosis. As aA trigger factor could be underlined tooth or even multiple
teeth extraction and placement of dental implants. In differentDifferent retrospective studies
are shown showed that 1.6% to 14.8% of patients treated i.v.through IV with BPs for longer
than a year period of time and have developed osteonecrosis developed after tooth extraction.
According to a research done by Carlos Pigrau – –Serralach et al since 2014, BONJ reachescases
have reached 30.2% Viridance since 2014. Viridans group Streptococcistreptococci are isolated
in 83.3% formfrom the cases and AcctinomycesActinomyces spp in 39.0% from all bone
histological samples.
According to other studies, between 52% and 61% from all cases described of osteonecrosis of
patientscases treated with bisphosphonates are triggered after surgical treatment – –a per‐
centage that is extremely high. Retrospective research done by Kunchur R,., Need A,., Hughes
T,., et al. in 2009, says stated that from0.5% out of 194 patients treated with oral bisphospho‐
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nates have developed osteonecrosis occurrence is 0.5% after tooth extraction. They assumeas‐
sumed that dental implant placement iswas with similar biological load as tooth extraction.
Moreover, Donggeol Lee reportsreported that 77 patients treated with bisphosphonate
undergounderwent implantology treatment, with 78 placed implants with 97.4% success equal
to success in normal conditions. Sebastien Hoefert and Harald Eufinger report i.v.reported IV
and per os antibiotic treatment in bisphosphonate treated patients before surgical treatment.
In 2009, P. Pechalova, A. Bakardjiev, B. Vladimirov, E. Poryazova, I. Angelova, and A. Jeleva
publishpublished a case of a patient with bisphosphonate osteonecrosis of the mandible of a
patient after consistent oral intake of 14 month consistent intake for fourteen months of
FosamaxR (alendronate) (70mg per week dosage, taken once a week) and BonvivaR (ibadro‐
nate) (150mg month dosage, taken once a month) on the occasion ofdue to severe osteoporosis
with pathological fractures of vertebras. The oddly think in the case published is bone
sequester covered entirely with mucosa. Without fistula..
A group formfrom ITI (Bornstein, Cionca, Momblli)), based on a vast literature in 2009
differentiate, differentiated the surgeon behavior in patients with oral and i.v.IV bisphospho‐
nate intake. They assumeassumed that, in addition to the way of intake there is, the duration
of intake played an important role of the duration.. They saysaid that patients with osteopo‐
rosis/osteopenia take much lower dosage of bisphosphonate compared to cancer patients and,
thus, the accumulation of the medicine should be several years. This is enough to conclude
that In conclusion, patients who underwent oral surgical procedures are withhave significantly
lower risk of necrosis in these patientscompared to those who had IV bisphosphonate intake.
Similar conclusions are were made by our team on the basis of 3 treatedthree patients in 3
yearswho underwent treatment for the period of three years. One of the patients were onhad
an oral intake of bisphosphonates, one i.v.had IV, and one on DenozumabeDenosumabe
(subcutaneоus) As part of our). Our entire biological concept treatment include includes
preliminary antibiotic treatment, irrigation with chlorxeidine solutions, general and local
ozone therapy, hyperbaric chamber, PRGF usage, Er;Yag:YAG laser, photodynamic therapy,
and minimally invasive surgical techniques.
7. Conclusions
During an surgical, respectively a surgery, such as implantology treatment, especially in
bisphosphonate treated patients it is vital antibiotics preparation and is vital for the primary
healing process to be guaranteed, especially in bisphosphonate treated patients. Usage of
Clindamycin as osteotopicosteotropic antibiotics is a gold standard assuring lackto ensure
absence of post-operation infection and prevention of complications. LackThe absence of
dehiscence assureensures us smooth osteointegration process and lack of bone lose. That is
whyFor this purpose, the common requirements for soft tissue management, include suitable
implantology system, proper operation technique, atraumatic preparation, and last but not
least proper suturing materials and technique. Implantology has extra sources like PRP, PRF,,
PRGF, which could be applied with great success if it’s needed. The high concentration of
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platelets rich in growth factors (PRGF) in the operation field contributecontributes to a light
and with lack of troublestrouble-free post-operative process, guaranteeing perfect conditions
for the osteointegration process. In cases of post-operative complications MethronidazoleMe‐
tronidazole is a matter of choice.
8. Clinical cases
8.1. Case 1
The patient has arrived at our clinic for the first time in 2009 with pain syndrome, periodontal
abscess in the 47, 44, 31, 32, 41, and 42 area due to periodontitis developed formfrom the plaque
with periodontal pockets form 6from 6mm to 8mm.,combined with chronic occlusal trauma
from iatrogenic sharp edges of metal-ceramic constructions made years ago (X-ray, Fig. 1).
Based on the anamnesis, a treatment with medicines was found–6 months treatment with
Bonviva medicine–3mg once a month parenteral, associated with diagnosed osteopenia in 2007
with quantitative osteometry over tibia bone with T-score 2,9. It was considered that due to
the short-term treatment with the bisphosphonate medicine and the 5five-year period after it
by keepingto keep certain protocol for preparation and implantation, an implantology
treatment could be initiated. A multiple extraction of 47, 44, 42, 41, 31, and 32 was undertaken
after antibiotic protection, initial ultrasonic and sand-blasting therapy divided in tointo several
appointments, high-intensity and low intensity laser therapy, local and general ozone therapy
and hyperbaric therapy. Extraction sockets were filled with PRGF and sutured with PTFE. As
an additional prophylaxis measure from bisphosphonates induced osteonecrosis, photody‐
namic therapy was used. The healing process was without any complications.
The treatment plane includesplan included the entire sanitation of the mouth, periodontal and
endodontic preparation, and placement of 11 pieces titanium screwed implants. After uncov‐
ering of the implants, tooth 43 was planplanned for extraction despite the exact root-canal
treatment, due theto long term prognosis and high risk of root fracture. TillUntil that time, this
particular tooth was used for temporary fixed construction abutment. Because of the short
clinical crowns, crown-lengthening was planplanned and performed with Er:YAG laser, based
on the preliminary analysis of the size and shape of future prosthetic crowns and attached
gingiva available. X-ray surgical guide was made, along with a prototype of the future
prosthetic constructions, and was used for the CT. Due to the fact of previous bisphosphonate
usage, a certain surgical protocol was used again including: antibiotic prophylaxis, high-
intensity and low intensity laser therapy, local and general ozone therapy, hyperbaric therapy,
PRGF, precise soft-tissue management and photodynamic therapy. One implant was placed
in 15 area. Due to the lack of complications it was proceeded to, the placement of the rest of
the planned implants proceeded. Bone type was D4 for the maxilla and D3 for the mandible.
Bone spreaders were used for bone condensation. The primary stability of the implants was
15 up to 30 N/cm. Osteotomic implant beds were shaped by the usage of the existing surgical
guide. Existing bone doesdid not demandeddemand additional augmentative procedures.
Suture material was 4/0 PTFE. On the both jaws, fixed long-term temporary constructions
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waswere provided. After longer than usual period of waiting (more than ana year)), implants
were uncovered by half-thickness flaps moved apically. All 11 implants were osteointegrated.
After open-tray, impression technique with transfers zirconium abutments with titanium base
were made. CAD-CAM zirconium constructions were madmade directly on the same model.
In the frontal area constructions were made by blend-ceramic and distally full anatomy
zirconium.
Complete functional rehabilitation of the masticatory apparatus was achieved. Aesthetic
demands of the patient was covered completely.
Figure 6. Basic X-ray
Figure 7. Intraoral situation after preliminary treatment
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Figure 8. X-ray- before implant insertion
Figure 9. Minimal invasive insertion of the first implant
After preliminary treatment, the patient receivereceived one implnantimplant in the area of
the second upper right premolar (15) accompanied with clindamycin prophylaxis, PRGF
activation of the implant surface and covered by PRFG fibrin membrane, combined with
postimplantationpost implantation photodynamic therapy using PhotoSan® for 4 minutes,
two timetimes a day tilluntil the suture removal, and ozone therapy in the first three days
combined with hyperbaric-chambers.
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Figure 10. Implant insertion in second quadrant
Figure 11. Implant insertion in lower jowjaw
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The high concentration of platelets rich in growth factors (PRGF) in the operation field
contributecontributes to a light and with lack of troubles trouble-free post-operative process,
guaranteeing perfect conditions for the osteointegration process.
The process of tissue repair iswas based on a complex cascade of biological events controlled
by a long list of biologically active growth factors and proteins. The spatial and temporal action
of this family of mediators on the tissue-damaged area regulates the mechanisms and phases
that govern tissue repair and regeneration
Figure 12. Activation of implant surface with PRGF
Figure 13. PRGF membrane for covering of the implants
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Figure 14. Pure ozone injected subcutaneously in the manipulation area
Another method used in our biological concept is ozone therapy. There are several known
actions of ozone onin the human body, such as anti-microbial, immunostimulating, antihi‐
poxyc, analgesic, detoxicating, bioenergetics and biosynthetic (activation of the metabolism of
carbohydrates, proteins and lipids)), etc. Ozone is a relatively rare and unstable molecule
composed of three oxygen atoms O3. The normal oxygen molecule has two oxygen atoms O2.
Stratospheric ozone is important in the earth system because it absorbs ultraviolet radiation
from the sun, protecting life on earth. The beneficial biological effects of ozone, is its anti-
microbialantimicrobial activity. How we can derive ozon?the ozone? Using a simple electric
arc, we can produce ozone. In case, for example, of bone regeneration, for example, the purpose
of ozone using ozone is the initial local growth factor expression and stimulatetion stimulate
the migration of osteoprogenitor cells to the wound site and subsequentlyand subsequently,
in a controlled fashion, to direct their differentiation to the osteogenic cell line. Throughout
this process, another set of factors will regulate the dynamic equilibrium between cell inhibi‐
tion and proliferation, as well as angiogenesis and extracellular matrix formation. Ozone-
generator can introduce pure ozone in saline. Ozone infusion is also precious for the fact that
it generates a therapeutic effect on faster post op wound healing and preliminary preparation
of the patient by avoiding further complications and assuring on 99% smooth primary closure.
Anti-microbial effect of ozone asis a result of its action on cells by damaging its cytoplasmatic
membrane due to ozonolysis of dual bonds and also ozone-induced modification of intercel‐
lular contents because of secondary oxidants effects. This action is non-specific and selective
to microbial cells, it does not dameagedamage human cells because of their major antioxidative
ability. Ozone is very efficient in antibiotics resistant strains. Its anti-microbial activity
increases in liquid environment of acidic pH. In viral infections, the ozone action lies in the
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intolerance of infected cells to peroxides and change of activity of reverse transcriptase, which
takes part in synthesis of viral proteins.
Figure 15. Usage of photodynamic therapy contributecontributes to cell destruction of the microorganisms and pre‐
ventprevents complications and accelerateaccelerates wound healing
Figure 16. Photodynamic therapy with photodynamic intraoral tray
Immunopathology and Immunomodulation142
Figure 17. Minimal invasive extraction of 43- root separation
Figure 18. Minimal invasive extraction of 43
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Figure 19. Granulation tissue ablation with Er:YagYAG laser
Figure 20. Palatal connective tissue graft
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Figure 21. Palatal connective tissue graft in PRGF
Figure 22. Bone graft material mixed with PRGF
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Figure 23. Bone graft material mixed with PRGF in postextractionpost-extraction socket
Figure 24. PRGF-clot cloth
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Figure 25. Covering of bone graft material with the PRGF clotcloth
Figure 26. Suturing of the palatal connective tissue graft over the postextracted socetpost-extracted socket
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Figure 27. Soft healing process
Figure 28. The end result
Figure 29. End result after treatment
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8.2. Case 2
A female patient, 57 years old, S. H. in good general good health, non-smoker, was received
at the clinic with complainscomplaints of mobility of the entire upper jaw prosthetic fixed
construction, accompanied with pain and inability to eat, dating back to 3 months earlier.
Clinical exam findfound out significant mobility (4th degree by Miller) of metal-ceramic fixed
one-piece bridge prosthetic construction of the upper jaw. (Fig. 2). On the X-ray (Fig.1), 4
screwing dental implants arewere observed, “Tramonte design” and 4four residual roots were
in terminal stage. There iswas a significant bone resorption around the implants visible on the
x-ray (proven lack of osteointegration.). From the patient histori ispatient’s history, it was
known that these implants arewere placed 5five years ago. AnA year later, patient beginsbegan
treatment with Fozamax per os once a week withfor the duration 2of two years because of
osteoporosis diagnosediagnosis (T-scorscore-2.9%).
Figure 30. Initial X-ray
Figure 31. Intraoral view
After initial periodontal therapy, with ultrasonic device and highintensityhigh intensity laser,
under antibiotic cover (clindamycin 600mg. /./8h per os), 2two times hyperbaric chamber
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before and three times after the dental procedures, saline enriched with ozone 9nine times and
three were locally applied subcutaneously, photodynamic therapy tilluntil the 10th den after
the dental procedure of removing all residual roots and implants. In the extraction sockets
were placed PRGF cloth, collagen sponge and the wound were sutured. Post-operative period
was smooth without any pain or complications. The patientspatient was given an immediate
fabricated total removable dentures.
Figure 32. Intraoral view after bridge removal
Figure 33. All implants, teeth and bridge after removal
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Figure 34. Granulation tissue ablation with Er:YagYAG laser
Figure 35. PRGF – cloth
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Figure 36. Covering with collagen sponge and suturing
Figure 37. Day after surgery
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Figure 38. Ten days after surgery
Figure 39. Three weeks after surgery
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Figure 40. Intraoral view after implant insertion
Figure 41. Intraoral view after suturing
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Figure 42. Two weeks after surgery
Figure 43. Panoramic X-ray after surgery
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Figure 44. Four weeks after surgery
8.3. Case 3
A female patient, 54 years old, in good general health condition, smoker (over 10 cigarettes
per day), was received at the clinic with complainscomplaints from fixed prosthetic construc‐
tion mobility on the upper jaw, poor aesthetics, and inability to eat normally. X-ray proves
anand aggressive periodntoalperiodontal disease with more than 9-10mm910mm bone
resorption of interdental bone. PatientPatient’s history sayssaid that she is was on Denosu‐
mabdenosumab (subcutaneously every 6 months) during for the last 3three years –in treatment
for osteoporosis diagnose. The treatment plan was similar with case N2 and the healing process
went smoothsmoothly.
Figure 45. Intraoral view
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Figure 46. Postextracted sockets
Figure 47. The extracted teeth
Figure 48. Granulation tissue ablation with Er:YagYAG laser
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Figure 49. PRGF clotcloth
Figure 50. Covering with collagen sponge and suturing
Figure 51. The immediate denture
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Figure 52. Three weeks after extraction
*All case-pictures are Dr. Abadzhiev’s private practice patiens.
Table 1. Usage and dosage of the bisphosphonates
After R.E. Marx
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MRONJ† Staging Treatment Strategies‡
At risk category No apparent necrotic bone in patients
who have been treated with either oral or IV
bisphosphonates
⋅ No treatment indicated
⋅ Patient education
Stage 0 No clinical evidence of necrotic bone, but non-
specific clinical findings, radiographic changes and
symptoms
⋅ Systemic management, including the use of pain
medication and antibiotics
Stage 1 Exposed and necrotic bone, or fistulae that probes
to bone, in patients who are asymptomatic and have no
evidence of infection
⋅ Antibacterial mouth rinse
⋅ Clinical follow-up on a quarterly basis
⋅ Patient education and review of indications for
continued bisphosphonate therapy
Stage 2 Exposed and necrotic bone, or fistulae that probes
to bone, associated with infection as evidenced by pain
and ery- themaerythema in the region of the exposed bone
with or without purulent drainage
⋅ Symptomatic treatment with oral antibiotics
⋅ Oral antibacterial mouth rinse
⋅ Pain control
⋅ Debridement to relieve soft tissue irritation and infection
control
Stage 3 Exposed and necrotic bone or a fistula that probes
to bone in patients with pain, infection, and one or more of
the fol- lowingfollowing: exposed and necrotic bone
extending beyond the region of alveolar bone,(, (i.e.,.
inferior border and ramus in the mandible, maxillary
sinus and zygoma in the maxilla) resulting in pathologic
fracture, extra-oral fistula, oral antral/oral nasal
communication, or osteolysis extending to the inferior
border of the mandible of sinus floor
⋅ Antibacterial mouth rinse
⋅ Antibiotic therapy and pain control
⋅ Surgical debridement/resection for longer term palliation
of infection and pain
Table 2. Staging and Treatment Strategies
Position Paper of American Association of Oral and Maxillofacial Surgeons (2014)
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